Skip to Content
Merck

Inhibition of the NLRP3 inflammasome prevents ovarian aging.

Science advances (2021-02-02)
José M Navarro-Pando, Elísabet Alcocer-Gómez, Beatriz Castejón-Vega, Elena Navarro-Villarán, Mónica Condés-Hervás, María Mundi-Roldan, Jordi Muntané, Antonio J Pérez-Pulido, Pedro Bullon, Chun Wang, Hal M Hoffman, Alberto Sanz, Gabriel Mbalaviele, Bernhard Ryffel, Mario D Cordero
ABSTRACT

Inflammation is a hallmark of aging and is negatively affecting female fertility. In this study, we evaluate the role of the NLRP3 inflammasome in ovarian aging and female fertility. Age-dependent increased expression of NLRP3 in the ovary was observed in WT mice during reproductive aging. High expression of NLRP3, caspase-1, and IL-1β was also observed in granulosa cells from patients with ovarian insufficiency. Ablation of NLRP3 improved the survival and pregnancy rates and increased anti-Müllerian hormone levels and autophagy rates in ovaries. Deficiency of NLRP3 also reduced serum FSH and estradiol levels. Consistent with these results, pharmacological inhibition of NLRP3 using a direct NLRP3 inhibitor, MCC950, improved fertility in female mice to levels comparable to those of Nlrp3-/- mice. These results suggest that the NLRP3 inflammasome is implicated in the age-dependent loss of female fertility and position this inflammasome as a potential new therapeutic target for the treatment of infertility.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cetrorelix acetate, ≥98% (HPLC)